SK pharmteco Expands into Cell and Gene Therapy With the Acquisition of French CDMO Yposkesi

SK pharmteco Expands into Cell and Gene Therapy
With the Acquisition of French CDMO Yposkesi

Rancho Cordova, California, April 28, 2021

SK pharmteco, a global contract development and manufacturing organization (CDMO) specializing in the manufacture of active pharmaceutical ingredients (APIs) and advanced intermediates, recently announced the acquisition of the major interest in Yposkesi. Yposkesi is a leading CDMO focusing on producing gene therapy drugs with one of the largest GMP manufacturing facilities in Europe of lentiviral and AAV vectors.

SK pharmteco CEO, Dr. Aslam Malik, shares “Yposkesi brings key biological capabilities, at commercial scale, to SK pharmteco.” “We are delighted to welcome their impressive team and talents to ours and believe jointly we will offer still broader CDMO capabilities to our pharmaceutical and biopharmaceutical customers worldwide” adds Dr. Malik.

Going forward Yposkesi will operate in a mode similar to other SK pharmteco operations, AMPAC Fine Chemicals, SK biotek Korea and SK biotek Ireland, wherein each individual company maintains its individual culture and identity while sharing best practices and collectively offering a customer facing corporate presence to the market as SK pharmteco.

Contact: Patrick Park +1 (916) 357-6376
Website: www.skpharmteco.com
SOURCE: SK pharmteco

Scroll to Top